Sanofi Consumer Healthcare India Performance Analyzed

Sanofi Consumer Healthcare India recently announced that Narahari Naidu, their Chief Financial Officer, is leaving to pursue other ventures. His departure is official and set to take effect at the end of the trading day on October 15, 2025. This change happens as the company is now operating independently, focusing solely on consumer health products.

Key Points

• Sanofi Consumer Healthcare India’s CFO, Naidu, is departing.
• Departure effective October 15, 2025, marking final day.
• Company now independent, concentrating on consumer health products.
• Revenue increased 28% year-on-year to Rs 220.9 crore.
• Profit after tax up 21% to Rs 60.7 crore.
• Stock price decreased by 0.84% to Rs 4,624 on BSE.

The company’s shift happened after a significant move: on June 1, 2024, Sanofi Consumer Healthcare India separated from Sanofi India. Now, it concentrates on products like allergy relief (Allegra), digestive health (DePURA), pain management (Avil), and vitamins (Combiflam), among others. These products are central to their business strategy.

Recent financial results show strong growth. In Q2 2025, revenue jumped 28% to Rs 220.9 crore. This growth was largely driven by sales abroad and the successful introduction of new products to the market.

Profit also saw a substantial increase. The company’s profit after tax reached Rs 60.7 crore, representing a 21% boost compared to Q1 2025. This also reflects a massive 109% rise from the same quarter last year (Q2 2024).

Despite this strong performance, the company’s stock experienced a slight decline, falling 0.84% to Rs 4,624 on the BSE. This highlights the need for ongoing monitoring of market trends.

Ultimately, Sanofi Consumer Healthcare India’s strategic changes and financial results demonstrate a powerful and evolving business model.